News

The drug is the first on-demand off episode treatment to be administered sublingually.

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.

The data support the need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening and diagnosing patients.

The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.

Findings from an analysis of a large population of individuals suggest that the blood immunoassay can predict tau and amyloid-ß pathologies, as well as differentiate and identify Alzheimer disease across the clinical spectrum.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.

In addition to the 2020 CMSC Virtual Meeting, attendees will be eligible to earn up to an additional 18 contact hours of continuing education.

Recipients of the award will be provided additional funding that will go to support porgrams for MS patients and their care partners.

The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.

Compared to those with normal fasting glucose levels, those with Type 2 diabetes had poorer cognitive performance at 3 and 6 months after suffering a stroke, based on data from the STROKOG consortium.

Cure SMA joins the list of influential and impactful organizations within the Strategic Alliance Program.

Contrary to prior literature, a new single-center analysis suggests that obstructive sleep apnea is not associated with delirium in those who were postoperatively admitted to the ICU, though PAP may reduce delirium in this patient population.